PURE Bioscience, Inc. (OTCMKTS:PURE – Get Free Report) saw a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 36,200 shares, a growth of 1,710.0% from the January 31st total of 2,000 shares. Based on an average daily volume of 35,300 shares, the short-interest ratio is presently 1.0 days.
PURE Bioscience Price Performance
Shares of PURE stock opened at $0.06 on Friday. The firm’s 50-day moving average is $0.07 and its two-hundred day moving average is $0.08. The company has a market capitalization of $6.71 million, a PE ratio of -1.50 and a beta of 0.13. PURE Bioscience has a 12 month low of $0.06 and a 12 month high of $0.16.
PURE Bioscience (OTCMKTS:PURE – Get Free Report) last released its quarterly earnings results on Monday, December 16th. The company reported ($0.01) earnings per share (EPS) for the quarter.
About PURE Bioscience
PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds.
Recommended Stories
- Five stocks we like better than PURE Bioscience
- What is the Hang Seng index?
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- How Technical Indicators Can Help You Find Oversold Stocks
- MarketBeat Week in Review – 02/24 – 02/28
- Market Cap Calculator: How to Calculate Market Cap
- 3 Companies Buying Back Stock – Why They’re Doubling Down
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.